Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome

被引:162
|
作者
Matricon, J. [1 ,2 ]
Meleine, M. [1 ,2 ]
Gelot, A. [3 ]
Piche, T. [4 ]
Dapoigny, M. [5 ]
Muller, E. [1 ,2 ]
Ardid, D. [3 ]
机构
[1] Univ Auvergne, Clermont Univ, NEURO DOL, Clermont Ferrand, France
[2] INSERM, Clermont Ferrand, France
[3] Univ Auvergne, Clermont Univ, Inst Univ Technol, Aubiere, France
[4] Hop Archet II, CHU Nice, INSERM, Serv Gastroenterol,U576, Nice, France
[5] CHU Clermont Ferrand, Hotel Dieu, Serv Hepatogastroenterol, Clermont Ferrand, France
关键词
STRESS-RELATED ALTERATIONS; DIARRHEA-PREDOMINANT IBS; CELL COUNTS CORRELATE; MUCOSAL MAST-CELLS; FECAL LACTOFERRIN; VISCERAL HYPERSENSITIVITY; ABDOMINAL-PAIN; GASTROINTESTINAL DIAGNOSIS; ENTEROCHROMAFFIN CELL; INFLAMMATORY MARKERS;
D O I
10.1111/apt.12080
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Irritable bowel syndrome (IBS), one of the most common gastrointestinal disorders, markedly impairing patients' quality of life. Drug development for IBS treatment has been hampered by the lack of understanding of IBS aetiology. In recent years, numerous data have emerged that suggest the involvement of immune activation in IBS, at least in a subset of patients. Aim To determine whether immune activation and intestinal permeabilisation are more frequently observed in IBS patients compared with healthy controls. Methods The scientific bibliography was searched using the following keywords: irritable bowel syndrome, inflammation, immune activation, permeabilisation, intestine, assay, histology and human. The retrieved studies, including blood, faecal and histological studies, were analysed to provide a comprehensive and structured overview of the available data including the type of assay, type of inflammatory marker investigated or intestinal segment studied. Results Immune activation was more frequently observed in IBS patients than in healthy controls. An increase in the number of mast cells and lymphocytes, an alteration in cytokine levels and intestinal permeabilisation were reported in IBS patients. No consistent changes in the numbers of B cells or enterochromaffin cells or in mucosal serotonin production were demonstrated. Conclusions The changes observed were modest and often heterogeneous among the studied population. Only appropriate interventions improving irritable bowel syndrome symptoms could highlight and confirm the role of immune activation in this pathophysiology.
引用
收藏
页码:1009 / 1031
页数:23
相关论文
共 50 条
  • [31] Intestinal and systemic immune markers in patients with Irritable Bowel Syndrome
    Mujagic, Z.
    Tigchelaar, E.
    Smolinska, A.
    Zhernakova, S.
    Baranska, A.
    Swertz, M.
    Masclee, A.
    Van Schooten, F. -J.
    Wijmenga, C.
    Jonkers, D.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2014, 26 : 34 - 34
  • [32] Associations of Clinical Symptoms and Bowel Characteristics With Intestinal Microbiota in Patients With Irritable Bowel Syndrome
    Ringel, Yehuda
    Ringel-Kulka, Tamar
    Salojarvi, Jarkko
    Carroll, Ian
    De Vos, Willem
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S764 - S764
  • [33] Review article: linaclotide for the management of irritable bowel syndrome with constipation
    Layer, P.
    Stanghellini, V.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (04) : 371 - 384
  • [34] Review article: the complexity of drug development for irritable bowel syndrome
    Kamm, MA
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (03) : 343 - 351
  • [35] A systematic review and meta-analysis of the associations between endometriosis and irritable bowel syndrome
    Saidi, Khadija
    Sharma, Shantanu
    Ohlsson, Bodil
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2020, 246 : 99 - 105
  • [36] Review article: clinical pharmacology models of irritable bowel syndrome
    Malagelada, JR
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 : 57 - 64
  • [37] MESALAZINE TREATMENT FOR INTESTINAL IMMUNE ACTIVATION IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: A RANDOMIZED CONTROLLED PILOT TRIAL
    Barbara, G.
    Cremon, C.
    Gargano, L.
    De Giorgio, R.
    Cogliandro, R.
    Stanghellini, V.
    Corinaldesi, R.
    DIGESTIVE AND LIVER DISEASE, 2008, 40 : S4 - S5
  • [38] Mesalazine treatment for intestinal immune activation in patient with irritable bowel syndrome: A randomized controlled pilot trial
    Barbara, Giovanni
    Cremon, Cesare
    Gargano, Luciana
    De Giorgio, Roberto
    Cogliandro, Rosanna
    Stanghellini, Vincenzo
    Corinaldesi, Roberto
    GASTROENTEROLOGY, 2008, 134 (04) : A546 - A546
  • [39] Intestinal permeability and effect of NSAIDs on permeability in irritable bowel syndrome patients compared to healthy subjects
    Kerckhoffs, Angele
    Samsom, M.
    de Smet, M.
    Akkermans, Lma
    Renooij, W.
    GASTROENTEROLOGY, 2006, 130 (04) : A241 - A242
  • [40] Stool and urine trefoil factor 3 levels: associations with symptoms, intestinal permeability, and microbial diversity in irritable bowel syndrome
    Heitkemper, M. M.
    Cain, K. C.
    Shulman, R. J.
    Burr, R. L.
    Ko, C.
    Hollister, E. B.
    Callen, N.
    Zia, J.
    Han, C. J.
    Jarrett, M. E.
    BENEFICIAL MICROBES, 2018, 9 (03) : 345 - 355